Cleared Traditional

SCIMEDX PHASE II PR3 IGG ANTIBODY EIA

K010287 · Scimedx Corp. · Immunology
Mar 2001
Decision
44d
Days
Class 2
Risk

About This 510(k) Submission

K010287 is an FDA 510(k) clearance for the SCIMEDX PHASE II PR3 IGG ANTIBODY EIA, a Test System, Antineutrophil Cytoplasmic Antibodies (anca) (Class II — Special Controls, product code MOB), submitted by Scimedx Corp. (Denvill, US). The FDA issued a Cleared decision on March 16, 2001, 44 days after receiving the submission on January 31, 2001. This device falls under the Immunology review panel. Regulated under 21 CFR 866.5660.

Submission Details

510(k) Number K010287 FDA.gov
FDA Decision Cleared SESE
Date Received January 31, 2001
Decision Date March 16, 2001
Days to Decision 44 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement

Device Classification

Product Code MOB — Test System, Antineutrophil Cytoplasmic Antibodies (anca)
Device Class Class II — Special Controls
CFR Regulation 21 CFR 866.5660

Similar Devices — MOB Test System, Antineutrophil Cytoplasmic Antibodies (anca)

All 73
Anti-Neutrophil Cytoplasmic Antibodies (Ethanol-Fixed); Anti-Neutrophil Cytoplasmic Antibodies (Formalin-Fixed)
K243776 · Zeus Scientific · May 2025
EUROIMMUN IFA Granulocyte Mosaic? EUROPattern and EUROIMMUN EUROPLUS Granulocyte Mosaic? EUROPattern
K172582 · Euroimmun Us, Inc. · May 2018
AESKUSLIDES ANCA Ethanol, AESKUSLIDES ANCA Formalin
K172461 · Aesku.Diagnostics GmbH & Co. KG · Mar 2018
EliA PR3s Immunoassay; EliA MPOs Immunoassay; EliA GBM Immunoassay
K173792 · Phadia AB · Mar 2018
NOVA Lite DAPI ANCA Ethanol Kit, NOVA Lite DAPI ANCA Formalin Kit
K161258 · Inova Diagnostics, Inc. · Feb 2017
ELIA PR3S IMMUNOASSAY, ELIA MPOS IMMUNOASSAY, ELIA GBM IMMUNOASSAY, ELIA ANCA/GBM POSITIVE CONTROL 100, ELIA ANCA/GBM PO
K140225 · Phadia US, Inc. · Oct 2014